Aisling Capital Management LP reported 14 holdings worth US$472M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 13, 2026
Aisling Capital Management LP reported 14 holdings worth US$472M as of Jun 30, 2026. Largest: Bridgebio Pharma, Inc., Monte Rosa Therapeutics, Inc. and Syndax Pharmaceuticals, Inc. Filed Aug 13, 2026 (Form 13F).
- Holdings
- 14
- Value as reported
- US$472M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Bridgebio Pharma, Inc. | 4.59M | US$342M | 72.5% |
| Monte Rosa Therapeutics, Inc. | 1.56M | US$37.6M | 8.0% |
| Syndax Pharmaceuticals, Inc. | 1.32M | US$28.8M | 6.1% |
| Bicara Therapeutics Inc. | 569K | US$16.9M | 3.6% |
| Bridgebio Oncology Therapeutics, Inc. | 1.02M | US$7.76M | 1.6% |
| Scholar Rock Holding Corporation | 77,031 | US$4.24M | 0.90% |
| Biomea Fusion, Inc. | 2.05M | US$3.01M | 0.64% |
| Aclaris Therapeutics, Inc. | 434K | US$2.3M | 0.49% |
| Eupraxia Pharmaceuticals, Inc. | 325K | US$2.15M | 0.46% |
| Vtv Therapeutics Inc. | 50,000 | US$1.88M | 0.40% |
| Marker Therapeutics, Inc. | 325K | US$478K | 0.10% |
| Onkure Therapeutics, Inc. | 88,607 | US$404K | 0.09% |